<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989817</url>
  </required_header>
  <id_info>
    <org_study_id>VIP H-18050862</org_study_id>
    <nct_id>NCT03989817</nct_id>
  </id_info>
  <brief_title>The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers</brief_title>
  <official_title>The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoactive intestinal peptide (VIP) is a peptide of 28 amino acid residues that belongs to&#xD;
      the glucagon/secretin superfamily of peptides. It is produced in different regions of the&#xD;
      nervous system, including the brain, trigeminovascular system and several autonomic nerves.&#xD;
      Once released from neurons, it acts on vasoactive intestinal peptide receptor 1 (VPAC1),&#xD;
      vasoactive intestinal peptide receptor 2 (VPAC2) and pituitary adenylate cyclase-activating&#xD;
      polypeptide type I receptor (PAC1), by mediating smooth muscle relaxation, vasodilation and&#xD;
      water secretion. Along with other neuropeptides, such as calcitonin gene-related peptide&#xD;
      (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP), it is released from&#xD;
      the trigeminal afferents and exerts a strong vasodilating activity on the cranial&#xD;
      vasculature, sharing the activation of adenylate cyclase. Especially, it shares 70% structure&#xD;
      with PACAP and acts on the same receptors. But, unlike it, VIP cannot induce a long-lasting&#xD;
      vasodilation and has a modest capability to induce migraine attacks. Whether a long-lasting&#xD;
      infusion of VIP may induce a prolonged vasodilation in the cerebral vessels and migraine, as&#xD;
      a twenty-minute infusion of PACAP, is unknown.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cranial hemodynamic</measure>
    <time_frame>Before (-10 minutes) and after infusion (+2 hours) of VIP compared with before and after infusion of saline]</time_frame>
    <description>Change on diameter of superficial temporal artery. Change on diameter will be measured with milletimeter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and change of headache</measure>
    <time_frame>[Time Frame: Before (-10 minutes) and after infusion (+12 hours) of maxipost compared with before and after infusion of saline]</time_frame>
    <description>Occurrence of headache measured by numerical rating scale (NRS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Headache Disorders</condition>
  <arm_group>
    <arm_group_label>VIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To investigate the role of VIP on cranial hemodynamic and headache in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To investigate the role of saline on cranial hemodynamic and headache in healthy volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasoactive Intestinal Peptide (VIP) and Saline</intervention_name>
    <description>12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.</description>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>VIP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        18-60 years. 50-90 kg. Women of childbearing potential must use adequate contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Headache less than 48 hours before the tests start All primary headaches Daily consumption&#xD;
        of drugs of any kind other than oral contraceptives Pregnant or nursing women. A&#xD;
        cardiovascular disease of any kind, including cerebrovascular diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish headache center</name>
      <address>
        <city>KÃ¸benhavn S</city>
        <state>Danmark</state>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Mohammad Al-Mahdi Al-Karagholi</investigator_full_name>
    <investigator_title>MD, PhD student, Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoactive Intestinal Peptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

